Crossmark

Risk of cancer development associated with disease-modifying therapies for multiple sclerosis: study protocol for a systematic review and meta-analysis of randomised and non-randomised studies

Crossref DOI link: https://doi.org/10.1186/s13643-024-02677-z

Published Online: 2024-10-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Catalá-López, Ferrán https://orcid.org/0000-0002-3833-9312
Tejedor-Romero, Laura

Driver, Jane A.

Hutton, Brian

Sánchez-Ortí, Joan Vicent

Ridao, Manuel

Alonso-Arroyo, Adolfo

Correa-Ghisays, Patricia

Forés-Martos, Jaume

Balanzá-Martínez, Vicent

Valencia, Alfonso

Cobos, Inmaculada

Tabarés-Seisdedos, Rafael
License Information

Text and Data Mining valid from 2024-10-18

Version of Record valid from 2024-10-18
More Information

Article History

Received: 26 March 2024

Accepted: 4 October 2024

First Online: 18 October 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below